JAK2 and myeloproliferative neoplasm: We acknowledged the limitation of the retrospective design, as systematic exclusion of MPNs relied on EMR-documented diagnoses, and only 10 of 1145 erythrocytosis patients underwent JAK2 mutation testing, potentially missing MPN cases.